ABSTRACT
INTRODUCTION
Importantly, this vaccine has also been shown to protect horses from lethal HeV infection and 93 has been licensed for use by the equine industry in Australia (28). However, there has been no 94 study to date assessing performance of this vaccine in a nonhuman primate model of HeV 95 infection which is a necessary prerequisite prior to licensure of such a vaccine for use in humans.
96
Here, we report for the first time the prophylactic efficacy of the sG HeV vaccine in a lethal HeV 97 AGM model that faithfully recapitulates human HeV infection. 
MATERIALS AND METHODS

100
Statistics. Conducting animal studies in BSL-4 severely restricts the number of animal subjects, 101 the volume of biological samples that can be obtained and the ability to repeat assays follows: 100 μg of sG HeV and 2.5mg of aluminum ion (sG HeV + alum) per vaccinated animal.
122
The vaccine with CpG was formulated as follows: 100 μg of sG HeV , 2.5mg of aluminum ion, and 
138
Twelve adult AGMs weighing 3-6 kg (PreLabs, Hines, IL) were employed for this study.
139
Subjects were anesthetized by i.m. injection with ketamine and vaccinated with sG HeV by i.m.
140
injection on day -42 (prime) and day -21 (boost) (Fig. 1, black Finally, 125 μL of PBS was added to each well and incubated for 2 minutes as described above.
170
Samples were assayed for mean fluorescence intensity (MFI) across at least a 100 bead region intensity across 100 beads were determined for each sample and plotted.
174
HeV serum neutralization assays. Neutralization titers were determined by a conventional 175 serum neutralization assay. Briefly, sera were serially diluted twofold, and incubated with ~ 100 176 pfu of HeV for 1 hour at 37°C. Virus and antibodies were then added to individual wells of 6-177 well plates of Vero cells. Plates were stained with neutral red 2 days after infection and plaques
178
were counted 24 hours after staining. The 50% neutralization titer was determined as the serum 179 dilution at which at there was a 50% reduction in plaque counts versus control wells. virus was assessed by qRT-PCR on nasal, oral, and rectal swabs ( Fig. 2A, B , and C respectively) 257 with viremia also screened by qRT-PCR on whole blood samples (Fig. 2D ). HeV genome 258 equivalents were observed in all swab and blood samples for two of the control animals (R335
259
and O7521, Fig. 2 ) while we detected HeV genome equivalents for another control animal
260
(R372) in oral swabs on day 7 post-challenge (Fig. 2B, red) . The surviving control animal 261 (O7498) had no detectable HeV RNA in any sample. Likewise, none of the specifically 262 vaccinated animals had any detectable HeV RNA in any sample (negative data not shown). HeV
263
RNA was also detected systemically in the tissues of control animals R335 and O7521 (Fig. 3,   264 green and black respectively), whereas HeV RNA was only detected in the respiratory tissues,
265
the axillary LN, and femoral bone marrow for control animal O7521 (Fig. 3, red) . HeV RNA
266
was not detected in tissues of control animal O7498 or in any of the tissues of any of the 267 specifically vaccinated animals (negative data not shown). Detection of HeV RNA in tissues 268 (Fig. 3) , swabs, and blood ( Fig. 2 ) correlated with outcome and gross pathology (Fig. 1B and 269 Table 1 ) for each animal.
270
Histopathological and immunohistochemical analysis of HeV-infected AGMs.
271
Histopathology from the three control animals that succumbed to HeV challenge was mostly antigen was a notable finding within the endothelium of the brain stem (Fig. 4) . Representative (Fig. 4) . At the study endpoint, the tissue architecture was also normal in the control AGM that 289 survived (O7498); HeV antigen was also undetectable in tissues from this animal. Australian veterinarians reduced or ceased equine medicine in order to avoid contracting HeV.
308
In order to address this problem the Australian Government supported the commercial (Table 2) . Nevertheless, the present findings have clearly demonstrated that 335 sG HeV + alum alone is also capable of providing complete protection from HeV challenge.
336
As HeV and NiV replicate and cause severe pathology in the lung, and CpG motifs have Interestingly, all sG vaccinated animals were protected from lethal HeV challenge in the current 349 study, but the animals that received sG with CpG had significantly higher antibody titers.
350
Importantly, all specifically vaccinated animals were protected from HeV disease ( Fig.   351 1B, Table 1 ). Thrombocytopenia (d7); >2-fold increase in WBC (d8); > 2-fold increase in BUN (d8); 5-fold increase in CRE (d8); > 2-fold increase in AST (d8); >10-fold increase in CRP (d8); excess blood-tinged pleural fluid; inflated, enlarged lungs with multifocal areas of congestion and hemorrhage particularly of the lower and middle right lobes; darkened liver. 
